AB Plan für alle Bakterien :
Dr. med. Bernt - Dieter Huismans hat viel online aktuelle bereitgestellt,
wer hat Erfahrungen mit Huismans als Arzt ?
https://www.kabilahsystems.de/antibiosetherapieplan.pdf
Huismanns Links:
Chronische Lyme-Borreliose und Misch-Infektionen
WWWARCHIV,Information Sampler fuer Wissenschaft und Alltag,dr. huismans,huismans
https://www.xerlebnishaft.de/chronisch.pdf
https://www.erlebnishaft.de/staphylococcusaureus.pdf
https://www.xerlebnishaft.de/textauswahl.pdf
https://www.kabilahsystems.de/gegen.pdf
https://www.kabilahsystems.de/antibiosetherapieplan.pdf
https://www.xerlebnishaft.de/phytotherapie.pdf
https://www.kabilahsystems.de/atypical_mycobacteria.pdf
New Treatments for Chronic Infections Found in Fibromyalgia Syndrome
he recommended treatments for mycoplasmal blood infections require long-term antibiotic therapy,
usually multiple 6-week cycles of doxycycline (200-300 mg/d), ciprofloxacin or Cipro (1,500 mg/d), azithromycin or Zithromax (500 mg/d) and clarithromycin or Biaxin (750-1,000 mg/d). Multiple cycles are required, because few patients recover after only a few cycles [9], possibly because of the intracellular locations of mycoplasmas like M. fermentans and M. penetrans, and the slow-growing nature of these microorganisms. These responses are not due to placebo effects, because administration of some antibiotics, such as penicillins, resulted in patients becoming more not less symptomatic.
CFS/FMS/GWI patients with mycoplasmal infections generally respond to particular antibiotics (doxycycline, minocycline, ciprofloxacin, azithromycin and clarithromycin), and their long-term administration plus nutritional support, immune enhancement and other supplements appear to be necessary for recovery.
An Error Occurred Setting Your User Cookie
Mycoplasmas are the smallest free-living microorganisms, being about 300 nm in diameter.
They are bounded by a triple-layered membrane and, unlike conventional bacteria, do not
have a rigid cell wall. Hence, they are not susceptible to penicillins and other antibiotics that
act on this structure. They are, however, susceptible to a variety of other broadspectrum
antibiotics, most of which only inhibit their multiplication and do not kill them.
The
tetracyclines have always been in the forefront of antibiotic usage, particularly for genital
tract infections, but macrolides are also widely used for respiratory tract infections. Indeed,
in comparison with the tetracyclines, erythromycin, the newer macrolides, the ketolides and
the newer quinolones have equal or sometimes greater activity. The two latter antibiotic
groups also have some cidal activity. The antibiotic susceptibility profiles of several
mycoplasmas of human origin are presented, those of Mycoplasma pneumoniae and
Mycoplasma genitalium being similar. Apart from the penicillins, mycoplasmas are innately
resistant to some other antibiotics, for example the rifampicins. In addition, some may develop
resistance, either by gene mutation or by acquisition of a resistance gene, to antibiotics to
which they are usually sensitive. Resistance of mycoplasmas to tetracyclines is common and
due to acquisition of the tetM gene.
https://roczes.ovh.org/borelioza/An...s_and_treatment_of_mycoplasmal_infections.pdf
ost patients with CFS/FMS who have mycoplasma infection appear to recover and reach their pre-illness state after long-term antibiotic therapy with doxycycline, and the infection can not be detected after recovery.
Mycoplasma blood infection in chronic fatigue and fibromyalgia synd... - PubMed - NCBI
Oral erythromycin or one of the newer macrolides such as azithromycin or clarithromycin have long been the DOC for mycoplasmal respiratory tract infections. Tetracycline and its analogues are also active. Clindamycin is effective in vitro, but limited reports suggest it may not be active in vivo and thus is not considered a first-line treatment.
Fluoroquinolones such as levofloxacin or moxifloxacin exhibit bactericidal antimycoplasmal activity but are generally less potent in vitro than macrolides against M pneumoniae. Their advantage lies in the fact that they are active against all classes of bacteria that produce clinically similar respiratory tract infections, including macrolide-resistant S pneumoniae. As would be predicted by the lack of a cell wall, none of the beta-lactams is effective in vitro or in vivo against M pneumoniae, and neither are the sulfonamides or trimethoprim.[1]
The spread of macrolide resistance has led to development of real-time PCR-based assays to detect resistance genes directly in clinical specimens since cultures and conventional susceptibility tests require many more time.[21, 19, 20] In view of the increasing spread of macrolide resistance, clinicians are advised to monitor patient outcomes and to consider using alternative antimicrobial agents (eg, minocycline, doxycycline, tigecycline, fluoroquinolones) if an initial treatment with a macrolide is unsuccessful.[22]
Medscape: Medscape Access
The difficulty in eradicating Mycoplasma pneumoniae infections is due to the ability of the bacterium to persist within an individual, as well as the lack of cell wall in M. pneumoniae, which renders multiple antibiotics directed at the bacterial cell wall ineffective in treating infections.[2]
M. pneumoniae therefore displays resistance to antimicrobials such as β-lactams, glycopeptides, sulfonamides, trimethoprim, polymixins, nalidixic acid, and rifampin.[2][13] The majority of antibiotics used to treat M. pneumoniae infections are targeted at bacterial rRNA in ribosomal complexes, including macrolides, tetracycline, ketolides, and fluoroquinolone, many of which able to be administered orally.[2][14] Macrolides are capable of reducing hyperresponsiveness and protecting the epithelial lining from oxidative and structural damage, however they are capable only of inhibiting bacteria (bacteriostatic) and are not able to cause bacterial cell death
Mycoplasma pneumoniae - Wikipedia, the free encyclopedia